Hui Zhang1, Zhenzhen Zhang2, Xiaoding Liu1, Huanli Duan3, Tianmin Xiang2, Qiye He2, Zhixi Su2, Huanwen Wu1, Zhiyong Liang1. 1. Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China. 2. Singlera Genomics Inc. Shanghai, China. 3. Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Abstract
CONTEXT: Follicular thyroid carcinoma (FTC) is the second most common type of thyroid carcinoma and must be pathologically distinguished from benign follicular adenoma (FA). Additionally, the clinical assessment of thyroid tumors with uncertain malignant potential (TT-UMP) demands effective indicators. OBJECTIVE: We aimed to identify discriminating DNA methylation markers between FA and FTC. METHODS: DNA methylation patterns were investigated in 33 FTC and 33 FA samples using reduced representation bisulfite sequencing and methylation haplotype block-based analysis. A prediction model was constructed and validated in an independent cohort of 13 FTC and 13 FA samples. Moreover, 36 TT-UMP samples were assessed using this model. RESULTS: A total of 70 DNA methylation markers, approximately half of which were located within promoters, were identified to be significantly different between the FTC and FA samples. All the Gene Ontology terms enriched among the marker-associated genes were related to "DNA binding," implying that the inactivation of DNA binding played a role in FTC development. A random forest model with an area under the curve of 0.994 was constructed using those markers for discriminating FTC from FA in the validation cohort. When the TT-UMP samples were scored using this model, those with fewer driver mutations also exhibited lower scores. CONCLUSION: An FTC-predicting model was constructed using DNA methylation markers, which distinguished between FA and FTC tissues with a high degree of accuracy. This model can also be used to help determine the potential of malignancy in TT-UMP.
CONTEXT: Follicular thyroid carcinoma (FTC) is the second most common type of thyroid carcinoma and must be pathologically distinguished from benign follicular adenoma (FA). Additionally, the clinical assessment of thyroid tumors with uncertain malignant potential (TT-UMP) demands effective indicators. OBJECTIVE: We aimed to identify discriminating DNA methylation markers between FA and FTC. METHODS: DNA methylation patterns were investigated in 33 FTC and 33 FA samples using reduced representation bisulfite sequencing and methylation haplotype block-based analysis. A prediction model was constructed and validated in an independent cohort of 13 FTC and 13 FA samples. Moreover, 36 TT-UMP samples were assessed using this model. RESULTS: A total of 70 DNA methylation markers, approximately half of which were located within promoters, were identified to be significantly different between the FTC and FA samples. All the Gene Ontology terms enriched among the marker-associated genes were related to "DNA binding," implying that the inactivation of DNA binding played a role in FTC development. A random forest model with an area under the curve of 0.994 was constructed using those markers for discriminating FTC from FA in the validation cohort. When the TT-UMP samples were scored using this model, those with fewer driver mutations also exhibited lower scores. CONCLUSION: An FTC-predicting model was constructed using DNA methylation markers, which distinguished between FA and FTC tissues with a high degree of accuracy. This model can also be used to help determine the potential of malignancy in TT-UMP.
Authors: Veronika Mancikova; Raquel Buj; Esmeralda Castelblanco; Lucía Inglada-Pérez; Anna Diez; Aguirre A de Cubas; Maria Curras-Freixes; Francisco Xavier Maravall; Didac Mauricio; Xavier Matias-Guiu; Manel Puig-Domingo; Ismael Capel; María Rosa Bella; Enrique Lerma; Eva Castella; Jordi Lluis Reverter; Miguel Ángel Peinado; Mireia Jorda; Mercedes Robledo Journal: Int J Cancer Date: 2014-01-13 Impact factor: 7.396
Authors: Emmanuel Labourier; Alexander Shifrin; Anne E Busseniers; Mark A Lupo; Monique L Manganelli; Bernard Andruss; Dennis Wylie; Sylvie Beaudenon-Huibregtse Journal: J Clin Endocrinol Metab Date: 2015-05-12 Impact factor: 5.958
Authors: Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov Journal: J Clin Endocrinol Metab Date: 2003-05 Impact factor: 5.958